Arrowhead Receives $10M Option Exercise Fee From Janssen

• Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1.

• Receipt of the option notice earns Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) a $10 million option exercise fee.

• Janssen will now have all rights to develop and commercialize ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead's proprietary Targeted RNAi Molecule platform.

• "The collaboration with Janssen, which was executed in 2018, for ARO-HBV against chronic hepatitis B infection, and potentially three additional programs, has been highly productive and collaborative," said Chris Anzalone, President & CEO at Arrowhead.

• Price Action: JNJ shares are down 0.22% at $170.02 during the premarket session on the last check Tuesday. ARWR closed at $73.05 on Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• US Poised To Dispatch 20M Additional COVID-19 Shots To Countries In Need: CNBC

• J&J Cuts This Week's COVID-19 Vaccine Deliveries For EU By Half: Reuters

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.